SCIENTIFIC PROGRAM

Friday, October 16, 2015

08:40-09:20
Room 101
Plenary Lecture 2
Co-organized by Centers for Disease Control, Ministry of Health and Welfare
Moderator: Hsu-Sung Kuo (Taiwan)

PL 2
Novel Approaches to HIV Prevention
David D. Ho (USA)

09:20-10:00
Room 101
Plenary Lecture 3
Co-organized by Centers for Disease Control, Ministry of Health and Welfare
Moderator: Po-Ren Hsueh (Taiwan)

PL 3
HIV Treatment as Prevention: Building on the HIV Experience to Promote Healthcare Sustainability
Julio Montaner (Canada)

10:30-12:00
Room 101
Symposium 1
Co-organized by Centers for Disease Control, Ministry of Health and Welfare
Effective HIV Prevention Strategies for Key Populations
Moderators: Julio Montaner (Canada); Hsi-Hsun Lin (Taiwan)

SP 1-1
Strategies to Control the Expanding Global Pandemic of HIV/AIDS
Kenrad Nelson (USA)

SP 1-3
Effective HIV Prevention Strategies for Key Populations
Chi-Tai Fang (Taiwan)

10:30-12:00
Room 102
Symposium 2
Viral Diagnosis
Moderators: Sazaly Abu Bakar (Malaysia); Chuan-Liang Kao (Taiwan)

SP 2-1
Role of Virus Laboratory in the Prevention and Control of Severe Infectious Diseases: Thailand Experience
Prasert Thongcharoen (Thailand)

SP 2-2
Optimizing the Clinical Value of HPV Test
Paul K.S. Chan (Hong Kong)

SP 2-3
Surveillance at the Animal-human Interface and Large-scale Sequencing of Pathogens in Response to Public Health Emergency
Huachen Zhu (Hong Kong)

10:30-12:00
Room 103
Symposium 3
Emerging Infectious Diseases and Vaccine I
Moderators: Hsing-Jien Kung (Taiwan); Min-Shi Lee (Taiwan)

SP 3-1
Development of Cell-based Influenza H7N9 Vaccines for Pandemic Preparedness
Min-Shi Lee (Taiwan)

SP 3-2
Vaccination and Communication
David Salisbury (UK)

SP 3-3
The Temporal, Spatial and Evolutionary Dynamics of Ebola Virus in West Africa
Andrew Rambaut (UK)

10:30-12:00
Room 105
Oral Session 1
Influenza Virus / Basic Research
Moderators: Shin-Ru Shih (Taiwan); Kung-Chia Young (Taiwan)

OS 1-1
Host Factor TUFM Differentially Associates with Viral Protein and Impedes Avian-like Influenza a Virus Replication in Human Cells
Shu-Ming Kuo (Taiwan)

OS 1-2
The Role of Phosphodiesterase 3A in Influenza Virus Disease Severity and Viral Replication
Yin-Ming Lui (Hong Kong)

OS 1-3
MAPK Phosphatase 5 Expression Induced by Influenza Virus Negatively Regulates IRF3 Activation and Type I Interferon Response
Yongliang Zhang (Singapore)

OS 1-4
Infection Dynamics of Novel Influenza A Viruses Isolated from Australian Pigs
Joanne Taylor (Australia)

OS 1-5
Rosmarinic Acid Inhibits Influenza Virus by Suppressing Cellular AKT Phosphorylation
Jim-Tong Horng (Taiwan)

OS 1-6
Insights into Pre-existing T-cell Immunity to Influenza Infection From a Population-based Cohort Study in Singapore
Jung Pu Hsu (Singapore)

OS 1-7
Nuclear Exportation in Avian Influenza Virus Adaptation to Human Cells
Khwansiri Ninpan (Thailand)

OS 1-8
Angiopoietin-like 4 Increases Pulmonary Tissue Leakiness and Damage during Influenza Pneumonia
Liang Li (Singapore)

OS 1-9
Knocking Down of P65 Component of NF-B Effectively Down Regulates Pro-inflammatory Cytokines in Human Pulmunary Epithelial Cells Infected with Influenza Virus H9N2
Alireza Haghparast (Iran)

OS 1-10
Peptide Mimetic Inhibitors Fused to Human Carrier Proteins as Novel Therapeutics for Treating Respiratory Virus Infections
James Mahony (Canada)

13:30-15:00
Room 101
Symposium 4
Co-organized by Centers for Disease Control, Ministry of Health and Welfare
New Prevention Technology for HIV
Moderators: Kenrad Nelson (USA); Shan-Chwen Chang (Taiwan)

SP 4-1
Large Isoform of Mammalian Relative of DnaJ is a Major Determinant of Human Susceptibility to HIV-1 Infection
Li-Min Huang (Taiwan)

SP 4-2
Next-generation HIV PrEP and Other Considerations
Robert T. Chen (USA)

13:30-15:00
Room 102
Symposium 5
Enterovirus 71
Moderators: Shin-Ru Shih (Taiwan); Paul K.S. Chan (Hong Kong)

SP 5-1
The Suramin Derivative NF449 Interacts with the 5-fold Vertex of the Enterovirus 71 Capsid to Prevent Virus Attachment to PSGL-1 and Heparan Sulfate
Yorihiro Nishimura (Japan)

SP 5-2
Impact of Enterovirus 71 Evolution on Virulence and Antigenicity
Jen-Ren Wang (Taiwan)

SP 5-3
Long Term Outcome and Cognitive Function after E71 CNS Infections
Luan-Yin Chang (Taiwan)

13:30-15:00
Room 103
Symposium 6
Dengue Virus
Moderators: Chwan-Chuen King (Taiwan); Yi-Ling Lin (Taiwan)

SP 6-1
Dengue Virus NS1 Is a Viral Toxin That Activates Cells via TLR4: Is Dengue a Case of 'Aseptic' Shock?
Paul R. Young (Australia)

SP 6-2
NS1 Rapid Test for Detection of Dengue Virus Infection: Should We Use It?
Sazaly Abu Bakar (Malaysia)

SP 6-3
Dengue Virus Nnonstructural Protein 1 Antibody Therapy and Vaccine Strategy
Yee-Shin Lin (Taiwan)

13:30-15:00
Room 105
Oral Session 2
Viral Vaccine
Moderators: Mi-Hua Tao (Taiwan); Szu-Min Hsieh (Taiwan)

OS 2-1
The Evolution of Pandemic Influenza Virus Threats in Swine
Martha Nelson (USA)

OS 2-2
Characterization of a Monoclonal Antibody 4F3 Binding to the Haemagglutinin Proteins of Different Avian Influenza Viruses
Subha Sankar Paul (Singapore)

OS 2-3
Immune Memory to Influenza Hemagglutinin and Antigenic Drift
Hsin-Hang Chen (Taiwan)

OS 2-4
Heterologous and Heterosubtypic Neuraminidase-inhibiting Antibodies Elicited by Recombinant Protein Immunization
Suh-Chin Wu (Taiwan)

OS 2-5
Recombinant Adeno-vaccine Expressing Enterovirus 71-like Particles against Hand, Foot, and Mouth Disease
Yen-Hung Chow (Taiwan)

OS 2-6
End-of-study (Year 7) Follow-up on Efficacy and Safety of the Human Papillomavirus (HPV)-16/18 AS04-adjuvanted Vaccine Administered in Women Older than 25 Years
Maria Rowena Del Rosario-Raymundo (Philippines)

OS 2-7
Efficacy and Safety of the Human Papillomavirus (HPV)-16/18 AS04-adjuvanted Vaccine in Chinese Women: Event-triggered Analysis of a Randomized Trial
Dan Bi (Belgium)

OS 2-8
Human Papillomavirus (HPV)-16/18 AS04-adjuvanted Vaccine: Immunological Superiority of the 2-dose Schedule Versus 2-dose and 3-dose Schedules of HPV-6/11/16/18 Vaccine; Results of a Randomised, Multicentre, Immunogenicity Trial Up to Month 24
Anthony Pak-Yin Liu (Hong Kong)

OS 2-9
Sustained Non-inferiority of the Human Papillomavirus (HPV)-16/18 AS04-adjuvanted Vaccine when Given as 2-dose Schedules in 9–14-year-old Girls Versus Standard 3-dose Schedule in 15–25-year-old Women: A Randomized Trial
Shelly A Mcneil (Canada)

15:30-16:10
Room 101
Plenary Lecture 4
Moderator: Cheng-Hua Huang (Taiwan)

PL 4
New Insights Into Posttranslational Modifications and Host Partners of Influenza Virus
Michael M.C. Lai (Taiwan)

16:10-16:50
Room 101
Plenary Lecture 5
Moderator: Shang-Shyng Yang (Taiwan)

PL 5
Emerging Infectious Diseases: Avian Influenza and MERS
Malik Peiris (Hong Kong)